BRINP1

Summary

BRINP1 (BMP/retinoic acid inducible neural specific 1, HGNC:2687) is a protein-coding gene on chromosome 9q33.1, encoding BMP/retinoic acid-inducible neural-specific protein 1 (O60477). Plays a role in neurogenesis and brain development.

This gene is located within a chromosomal region that shows loss of heterozygosity in some bladder cancers. It contains a 5’ CpG island that may be a frequent target of hypermethylation, and it may undergo hypermethylation-based silencing in some bladder cancers.

Source: NCBI Gene 1620 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 13 total
• MANE Select transcript: NM_014618

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2687
Approved symbol	BRINP1
Name	BMP/retinoic acid inducible neural specific 1
Location	9q33.1
Locus type	gene with protein product
Status	Approved
Aliases	FAM5A
Ensembl gene	ENSG00000078725
Ensembl biotype	protein_coding
OMIM	602865
Entrez	1620

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000265922, ENST00000373964, ENST00000482797, ENST00000936748, ENST00000936749, ENST00000958983

RefSeq mRNA: 1 — MANE Select: NM_014618 NM_014618

CCDS: CCDS6822

Canonical transcript exons

ENST00000265922 — 8 exons

Exon	Start	End
ENSE00000723362	119238655	119238760
ENSE00000723367	119242047	119242216
ENSE00000723371	119248960	119249150
ENSE00000926953	119208719	119208941
ENSE00000926954	119213919	119214155
ENSE00001168324	119166629	119168224
ENSE00001168335	119313138	119313405
ENSE00003342941	119369056	119369435

Expression profiles

Bgee: expression breadth ubiquitous, 200 present calls, max score 96.95.

FANTOM5 (CAGE): breadth broad, TPM avg 3.8192 / max 193.2541, expressed in 507 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102267	3.5626	492
102268	0.1703	90
102266	0.0863	49

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	96.95	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.44	gold quality
entorhinal cortex	UBERON:0002728	96.07	gold quality
primary visual cortex	UBERON:0002436	95.75	gold quality
postcentral gyrus	UBERON:0002581	94.90	gold quality
occipital lobe	UBERON:0002021	93.88	gold quality
superior frontal gyrus	UBERON:0002661	93.83	gold quality
parietal lobe	UBERON:0001872	93.76	gold quality
Brodmann (1909) area 46	UBERON:0006483	92.94	gold quality
prefrontal cortex	UBERON:0000451	92.79	gold quality
frontal pole	UBERON:0002795	92.76	gold quality
frontal cortex	UBERON:0001870	92.14	gold quality
buccal mucosa cell	CL:0002336	92.07	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.98	gold quality
orbitofrontal cortex	UBERON:0004167	91.95	gold quality
right frontal lobe	UBERON:0002810	91.72	gold quality
temporal lobe	UBERON:0001871	91.59	gold quality
Brodmann (1909) area 10	UBERON:0013541	91.48	gold quality
cerebral cortex	UBERON:0000956	91.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.37	gold quality
neocortex	UBERON:0001950	91.36	gold quality
paraflocculus	UBERON:0005351	90.99	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.94	gold quality
telencephalon	UBERON:0001893	90.51	gold quality
Ammon’s horn	UBERON:0001954	90.29	gold quality
cerebellum	UBERON:0002037	90.22	gold quality
cerebellar hemisphere	UBERON:0002245	90.02	gold quality
cerebellar cortex	UBERON:0002129	90.01	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.69	gold quality
cortical plate	UBERON:0005343	89.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.38

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): REST

miRNA regulators (miRDB)

81 targeting BRINP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-495-3P	99.96	72.81	4197

Literature-anchored findings (GeneRIF, showing 10)

• DBCCR1 is involved in the process of bladder tumorigenesis (PMID:12442002)
• the prevalent inactivation of DBCCR1 seen at the expression level in astrocytomas is not primarily caused by genomic loss of the gene. (PMID:15643521)
• likely tumor suppressor for NSCLC;silencing through homozygous deletion or methylation of its promoter promotes progression (PMID:15746151)
• hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative malignancies (PMID:18264085)
• High DBC1 expression is associated with breast and lung cancer.. (PMID:20429629)
• Rxpression of DBC1 and SIRT1 is a significant prognostic indicator for breast carcinoma patients. (PMID:21056897)
• the stress-induced DBC1-SIRT1 interaction is important for cell fate determination following genotoxic stress. (PMID:22465953)
• we found that the SIRT1 modulators AROS and DBC1 have an impact on hsp70 transcription, HSF1 acetylation status, and HSF1 recruitment to the hsp70 promoter (PMID:23349863)
• DBC1 modulates the stability and function of the nuclear receptor Rev-erb-alpha. (PMID:23398316)
• Results found that the expression of DBCCR1 is significantly lower in the lung cancer tissues compared with adjacent non-tumor tissues of patients, and correlates with more advanced stages of cancer, and shorter survival of patients. Interestingly, DBCCR1 attenuates the expression of DNMT1, suggesting a reciprocal regulation between genetic silencing of cancer suppressor genes and activating DNA methylation. (PMID:28427182)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	brinp1	ENSDARG00000078302
mus_musculus	Brinp1	ENSMUSG00000028351
rattus_norvegicus	Brinp1	ENSRNOG00000005561

Paralogs (2): BRINP3 (ENSG00000162670), BRINP2 (ENSG00000198797)

Protein

Protein identifiers

BMP/retinoic acid-inducible neural-specific protein 1 — O60477 (reviewed: O60477)

Alternative names: Deleted in bladder cancer protein 1

All UniProt accessions (1): O60477

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in neurogenesis and brain development. May suppress cell cycle progression in postmitotic neurons by inhibiting G1/S transition.

Subcellular location. Cytoplasm.

Tissue specificity. Highly expressed in brain. Weakly expressed in heart, lung, skeletal muscle, kidney, thymus, prostate, testis and small intestine.

Miscellaneous. Silenced by methylation in 50% of bladder cancer cell lines.

Similarity. Belongs to the BRINP family.

Isoforms (3)

UniProt ID	Names	Canonical?
O60477-1	1	yes
O60477-2	2
O60477-3	3

RefSeq proteins (1): NP_055433* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR020864	MACPF	Domain
IPR033237	BRINP	Family
IPR057450	BRINP_EGF	Domain
IPR057671	BRINP_C	Domain

Pfam: PF01823, PF19052, PF25415

UniProt features (17 total): glycosylation site 7, sequence variant 4, splice variant 3, signal peptide 1, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60477-F1	77.88	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (7): 156, 433, 443, 553, 599, 631, 677

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 184 (showing top): GOBP_MEMORY, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_COGNITION, GOBP_BEHAVIOR, GOBP_CELLULAR_RESPONSE_TO_LIPID, LI_WILMS_TUMOR, GCANCTGNY_MYOD_Q6, GOBP_POSITIVE_REGULATION_OF_NEURON_DIFFERENTIATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, CAGCTG_AP4_Q5, GOBP_NEGATIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_MULTICELLULAR_ORGANISMAL_RESPONSE_TO_STRESS

GO Biological Process (21): behavioral fear response (GO:0001662), brain development (GO:0007420), short-term memory (GO:0007614), cell population proliferation (GO:0008283), gene expression (GO:0010467), proteasomal protein catabolic process (GO:0010498), central nervous system neuron differentiation (GO:0021953), central nervous system neuron development (GO:0021954), social behavior (GO:0035176), exploration behavior (GO:0035640), maternal behavior (GO:0042711), positive regulation of neuron differentiation (GO:0045666), negative regulation of mitotic cell cycle (GO:0045930), homeostasis of number of cells within a tissue (GO:0048873), negative regulation of neurogenesis (GO:0050768), protein stabilization (GO:0050821), cellular response to retinoic acid (GO:0071300), vocalization behavior (GO:0071625), nervous system development (GO:0007399), neurogenesis (GO:0022008), regulation of cell cycle (GO:0051726)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), dendrite (GO:0030425), neuronal cell body (GO:0043025), glutamatergic synapse (GO:0098978), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
behavior	3
central nervous system development	2
neuron differentiation	2
behavioral defense response	1
fear response	1
animal organ development	1
head development	1
memory	1
cellular process	1
macromolecule biosynthetic process	1
protein catabolic process	1
central nervous system neuron differentiation	1
neuron development	1
biological process involved in intraspecies interaction between organisms	1
parental behavior	1
positive regulation of cell differentiation	1
regulation of neuron differentiation	1
mitotic cell cycle	1
regulation of mitotic cell cycle	1
negative regulation of cell cycle	1
tissue homeostasis	1
homeostasis of number of cells	1
negative regulation of cell development	1
neurogenesis	1
regulation of neurogenesis	1
negative regulation of nervous system development	1
regulation of protein stability	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
system development	1
nervous system development	1
cell differentiation	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
neuron projection	1
dendritic tree	1
somatodendritic compartment	1
cell body	1

Protein interactions and networks

STRING

1426 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BRINP1	SMPDL3A	Q92484	975
BRINP1	PRF1	P14222	730
BRINP1	ASTN1	O14525	530
BRINP1	ABCC4	O15439	492
BRINP1	C2orf80	Q0P641	491
BRINP1	ASTN2	O75129	476
BRINP1	FHIP1A	Q05DH4	457
BRINP1	CNEP1R1	Q8N9A8	449
BRINP1	CCL14	Q16627	435
BRINP1	ALDH1A1	P00352	429
BRINP1	GPR26	Q8NDV2	429
BRINP1	ALOX15	P16050	425
BRINP1	WAC	Q9BTA9	423
BRINP1	BMPR1B	P78366	418
BRINP1	SMPD1	P17405	411

IntAct

13 interactions, top by confidence:

A	B	Type	Score
ZNF326	BRINP1	psi-mi:“MI:0914”(association)	0.580
ZNF326	BRINP1	psi-mi:“MI:0915”(physical association)	0.580
BRINP1	ZNF326	psi-mi:“MI:0915”(physical association)	0.580
BRINP1	HNRNPA1	psi-mi:“MI:0914”(association)	0.460
BRINP1	SIRT1	psi-mi:“MI:0915”(physical association)	0.400
BRINP1	CCND1	psi-mi:“MI:0915”(physical association)	0.370
BRINP1	RAC1	psi-mi:“MI:0915”(physical association)	0.370
BRINP1	HSPA5	psi-mi:“MI:0914”(association)	0.350
HNRNPA1	NUDT21	psi-mi:“MI:0914”(association)	0.350
GPC3	PXDNL	psi-mi:“MI:0914”(association)	0.350

BioGRID (51): PBXIP1 (Affinity Capture-MS), BRINP1 (Protein-peptide), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS), BRINP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0F7YYX3, A0A182IRF8, A0A1S4GYH9, A0A1S4GYJ6, A0A1S4HE90, B0X6Z1, B6DDQ8, F5HK49, G5EBL2, G5ECL4, M1JMQ7, O10309, O55183, O60477, P0CJ08, P0DQE5, P18153, P18301, P22815, P34404, P43648, P52823, P54194, P85831, P97574, Q06KA2, Q08264, Q09288, Q0IF93, Q10128, Q11077, Q16S34, Q24738, Q5E9L2, Q5MIW7, Q6P9Z6, Q7PJ76, Q7PN86, Q7PNF2, Q7ZZR3

Diamond homologs: O60477, Q499E0, Q5E9L2, Q5RDR5, Q6DFY8, Q76B58, Q7ZZR3, Q8K1M7, Q8K1M8, Q920P3, Q925T8, Q9C0B6, Q90X85

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

13 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	8
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2047 predictions. Top by Δscore:

Variant	Effect	Δscore
9:119176732:T:TA	donor_gain	1.0000
9:119195652:T:TA	donor_gain	1.0000
9:119208714:CTTA:C	donor_loss	1.0000
9:119208715:TTA:T	donor_loss	1.0000
9:119208716:TA:T	donor_loss	1.0000
9:119208717:A:AC	donor_gain	1.0000
9:119208718:C:CA	donor_loss	1.0000
9:119208718:C:CC	donor_gain	1.0000
9:119208718:CCT:C	donor_gain	1.0000
9:119208718:CCTCT:C	donor_gain	1.0000
9:119208937:CTCAT:C	acceptor_gain	1.0000
9:119208939:CAT:C	acceptor_gain	1.0000
9:119238650:CCTA:C	donor_loss	1.0000
9:119238651:CTAC:C	donor_loss	1.0000
9:119238652:TA:T	donor_loss	1.0000
9:119238653:ACCT:A	donor_loss	1.0000
9:119242041:CTGTA:C	donor_loss	1.0000
9:119242042:TGTA:T	donor_loss	1.0000
9:119242043:GTAC:G	donor_loss	1.0000
9:119242044:TAC:T	donor_loss	1.0000
9:119242045:A:C	donor_loss	1.0000
9:119242046:C:A	donor_loss	1.0000
9:119242212:CTCCC:C	acceptor_gain	1.0000
9:119242214:CCC:C	acceptor_gain	1.0000
9:119242215:CC:C	acceptor_gain	1.0000
9:119242215:CCC:C	acceptor_gain	1.0000
9:119242216:CC:C	acceptor_gain	1.0000
9:119242216:CCTG:C	acceptor_loss	1.0000
9:119242217:C:CC	acceptor_gain	1.0000
9:119242217:CT:C	acceptor_loss	1.0000

AlphaMissense

5080 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:119167206:A:G	C722R	1.000
9:119167271:C:G	R700P	1.000
9:119167394:C:T	G659E	1.000
9:119167395:C:A	G659W	1.000
9:119167609:C:A	W587C	1.000
9:119167609:C:G	W587C	1.000
9:119167611:A:G	W587R	1.000
9:119167611:A:T	W587R	1.000
9:119167645:C:A	W575C	1.000
9:119167645:C:G	W575C	1.000
9:119167647:A:G	W575R	1.000
9:119167647:A:T	W575R	1.000
9:119167659:G:C	H571D	1.000
9:119167675:G:C	N565K	1.000
9:119167675:G:T	N565K	1.000
9:119167793:A:G	L526P	1.000
9:119167849:G:C	S507R	1.000
9:119167849:G:T	S507R	1.000
9:119167851:T:G	S507R	1.000
9:119167988:C:G	C461S	1.000
9:119167989:A:G	C461R	1.000
9:119167989:A:T	C461S	1.000
9:119168020:G:C	C450W	1.000
9:119168021:C:T	C450Y	1.000
9:119168022:A:G	C450R	1.000
9:119168029:G:C	C447W	1.000
9:119168030:C:G	C447S	1.000
9:119168030:C:T	C447Y	1.000
9:119168031:A:G	C447R	1.000
9:119168031:A:T	C447S	1.000

dbSNP variants (sampled 300 via entrez): RS1000009629 (9:119363277 A>G), RS1000022107 (9:119343870 T>A,C), RS1000024338 (9:119277358 T>A), RS1000041104 (9:119301523 A>C,T), RS1000048569 (9:119292857 A>T), RS1000051869 (9:119346379 T>C), RS1000069647 (9:119168185 G>C), RS1000090088 (9:119209466 G>A,T), RS1000090128 (9:119205858 C>A,T), RS1000117150 (9:119299502 A>G,T), RS1000117474 (9:119289295 T>G), RS1000125546 (9:119261483 C>T), RS1000140849 (9:119308281 C>G), RS1000179184 (9:119178781 C>T), RS1000179769 (9:119326110 A>T)

Disease associations

OMIM: gene MIM:602865 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST002932_25	Manganese levels	1.000000e-06
GCST004790_2	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	6.000000e-07
GCST006606_12	Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)	9.000000e-08
GCST007327_32	Smoking status (ever vs never smokers)	7.000000e-09
GCST007628_4	Impulsivity (motor)	1.000000e-06
GCST008162_2	Hip circumference	1.000000e-06
GCST008477_18	Emphysema annual change measurement in smokers (adjusted lung density)	7.000000e-06
GCST008477_5	Emphysema annual change measurement in smokers (adjusted lung density)	7.000000e-06
GCST008526_71	Coffee consumption	5.000000e-06
GCST008647_43	Urinary sodium excretion	3.000000e-09
GCST009524_123	Household income (MTAG)	3.000000e-08
GCST011741_17	LDL cholesterol levels in HIV infection	5.000000e-06
GCST011741_2	LDL cholesterol levels in HIV infection	5.000000e-06
GCST011742_56	Triglyceride levels in HIV infection	4.000000e-06
GCST012316_4	ghrelin levels	7.000000e-08

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0008204	left ventricular diastolic function measurement
EFO:0008347	response to trastuzumab
EFO:0004653	response to TNF antagonist
EFO:0005413	joint damage measurement
EFO:0004318	smoking behavior
EFO:0006946	behavioural disinhibition measurement
EFO:0007626	emphysema imaging measurement
EFO:0006781	coffee consumption measurement
EFO:0009282	sodium measurement
EFO:0009695	household income
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0600001	ghrelin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	8
monomethylarsonous acid	affects acetylation, affects methylation, decreases expression	3
bisphenol A	decreases expression, increases methylation	2
trichostatin A	affects cotreatment, affects methylation, decreases reaction, increases expression	2
entinostat	increases expression, affects cotreatment	2
Decitabine	decreases reaction, affects expression, affects cotreatment, affects methylation	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	decreases expression	1
arsenite	increases methylation	1
sodium arsenite	decreases reaction, affects acetylation, decreases expression, affects cotreatment, affects methylation	1
perfluorooctanoic acid	decreases expression	1
benzo(e)pyrene	increases methylation	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
NSC668394	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Calcitriol	increases expression	1
Cisplatin	affects expression	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.